Sino Biopharmaceutical Limited (HKG: 1177) announced that TQC3403, a umeclidinium bromide/vilanterol inhalation powder aerosol independently developed by its subsidiary Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), has been approved for marketing for the long‑term maintenance treatment of chronic obstructive pulmonary disease (COPD) – becoming the first domestically approved generic version of GSK’s originator product Anoro.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Marketing approval – generic |
| Product | TQC3403 – umeclidinium bromide/vilanterol inhalation powder aerosol |
| Indication | Long‑term maintenance treatment of COPD |
| Developer | Jiangsu Chia Tai Tianqing (CTTQ), subsidiary of Sino Biopharmaceutical (HKG: 1177) |
| Reference Product | GSK’s Anoro (umeclidinium/vilanterol) |
| First‑in‑China Distinction | First dual‑bronchodilator inhalation formulation to complete a head‑to‑head Phase III clinical validation study in China |
| Approval Date | 22 Oct 2026 |
Drug Profile & Manufacturing Complexity
- Composition: A fixed‑dose combination of two bronchodilators – umeclidinium bromide, a long‑acting muscarinic antagonist (LAMA), and vilanterol, a long‑acting β2‑agonist (LABA) – achieving long‑acting bronchodilation through complementary mechanisms with once‑daily dosing.
- Class Position: LAMA/LABA dual bronchodilation is a guideline‑preferred maintenance backbone for symptomatic COPD, offering superior airflow improvement versus monotherapy.
- Technical Barrier: The inhalation powder aerosol belongs to the high‑technological‑barrier “drug‑device combination” field – a single dose at the microgram level with blood concentrations of only picograms, where device engineering and aerosolization performance are as critical as the molecule itself.
- Formulation Challenge: The dual‑active‑ingredient combination additionally requires ensuring the uniformity and stability of both components in the formulation – a manufacturing hurdle that has limited the number of successful generic entrants worldwide.
- Generic First: TQC3403 is the first domestically approved generic of the umeclidinium/vilanterol franchise originally developed by GSK (Anoro), potentially introducing price competition to a major COPD maintenance category in China.
Clinical Evidence – Phase III Trial TQC3403‑CS‑01
| Endpoint | Result (TQC3403 vs. Originator) | Equivalence Criterion | Outcome |
|---|---|---|---|
| Change from Baseline in Pre‑dose Trough FEV₁ at Week 24 (Primary) | Least‑squares mean difference 16 mL (95% CI −30 to 62; p = 0.49) | Preset equivalence margin ±70 mL | Equivalence met |
| Safety Profile | Similar between the two groups | – | Comparable tolerability |
The pivotal Phase III TQC3403‑CS‑01 study involved 56 centers nationwide and enrolled 414 patients with moderate‑to‑severe COPD, randomized 1:1 to receive TQC3403 or the reference originator product for 24 weeks. The primary endpoint – change from baseline in pre‑dose trough FEV₁ at Week 24 – showed a between‑group difference of 16 mL, comfortably within the preset ±70 mL equivalence margin, confirming therapeutic equivalence with similar safety profiles. This is the first dual‑bronchodilator inhalation formulation in China to complete a head‑to‑head Phase III clinical validation study.
Market Impact & Outlook
- COPD Burden in China: COPD affects roughly 100 million Chinese adults and ranks among the country’s leading causes of death; expanding access to affordable once‑daily LAMA/LABA maintenance therapy addresses a major public‑health need.
- Generic Pricing Dynamics: First‑to‑market generic status positions TQC3403 favorably for volume‑based procurement (VBP) eligibility and formulary access, potentially capturing significant share from the originator product.
- Barrier as Moat: The drug‑device combination complexity that deterred competitors now protects CTTQ’s early‑mover position among domestic generics of inhaled dual bronchodilators.
- Respiratory Franchise Depth: The approval extends CTTQ/Sino Biopharm’s respiratory portfolio with a guideline‑core maintenance product, complementing existing COPD and asthma assets.
- Next Milestones: Commercial rollout and procurement participation; potential further respiratory pipeline approvals. Timing not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding commercialization, procurement access, market share capture, and sales potential of TQC3403 in China. Actual results may differ materially due to risks including pricing policy and volume‑based procurement outcomes, competitive generic entry, device and supply‑chain performance, and prescribing dynamics in the COPD maintenance market.-Fineline Info & Tech
